EUR 1.26
(0.8%)
Year | Operating Income | Operating Income Growth |
---|---|---|
2023 | -62.63 Million USD | N/A |
2022 | -2.67 Million USD | 0.0% |
2021 | -1.09 Million USD | N/A |
Year | Operating Income | Operating Income Growth |
---|---|---|
2024 Q2 | -11.75 Million USD | -40.34% |
2024 Q1 | -8.37 Million USD | 22.61% |
2023 Q3 | -10.18 Million USD | 69.95% |
2023 Q4 | -10.82 Million USD | -6.28% |
2023 Q2 | -33.9 Million USD | -339.24% |
2023 Q1 | -7.71 Million USD | 0.0% |
2022 Q3 | -1.06 Million USD | -15.21% |
2022 FY | -27.16 Million USD | 0.0% |
2022 Q2 | -927 Thousand USD | 0.0% |
Name | Operating Income | Operating Income Difference |
---|---|---|
BioNTech SE | 690.4 Million EUR | 109.073% |
CureVac N.V. | -274.2 Million EUR | 77.157% |
Biotest Aktiengesellschaft | 143.5 Million EUR | 143.65% |
Biotest Aktiengesellschaft | 143.5 Million EUR | 143.65% |
BRAIN Biotech AG | -6.71 Million EUR | -832.807% |
Formycon AG | -369 Thousand EUR | -16875.068% |
Heidelberg Pharma AG | -21.2 Million EUR | -195.326% |
Medigene AG | -16.14 Million EUR | -287.875% |